MLTX FY2025 EPS Forecast Decreased by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has decreased its FY2025 earnings per share (EPS) forecast for MoonLake Immunotherapeutics to ($3.21), down from ($2.72), with a consensus estimate currently at ($1.79) EPS.
• The company holds a market capitalization of $3.82 billion and has garnered a consensus rating of "Moderate Buy" among analysts.
• Recent price targets for the stock vary significantly, with firms like Goldman Sachs increasing their target from $74.00 to $82.00, while other analysts set targets ranging from $61.00 to $67.00.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for MoonLake Immunotherapeutics in a report issued on Tuesday, September 2nd. Cantor Fitzgerald analyst P. Agrawal now forecasts that the company will post earnings of ($3.21) per share for the year, down from their prior forecast of ($2.72). The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($1.79) per share. Cantor Fitzgerald also issued estimates for MoonLake Immunotherapeutics' FY2026 earnings at ($4.36) EPS.

A number of other brokerages have also issued reports on MLTX. Needham & Company LLC reaffirmed a "buy" rating and issued a $66.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Rothschild & Co Redburn initiated coverage on MoonLake Immunotherapeutics in a research note on Monday, July 28th. They issued a "neutral" rating and a $65.00 price target on the stock. Wolfe Research raised MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price target on the stock in a research note on Monday, May 19th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $67.00 price objective on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 3rd. Finally, The Goldman Sachs Group upped their price target on MoonLake Immunotherapeutics from $74.00 to $82.00 and gave the stock a "buy" rating in a report on Wednesday, August 6th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $74.43.

MoonLake Immunotherapeutics Stock Performance

Shares of NASDAQ:MLTX opened at $59.50 on Thursday. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.65 and a quick ratio of 16.65. The business's 50 day moving average price is $52.40 and its 200-day moving average price is $44.40. The firm has a market capitalization of $3.82 billion, a PE ratio of -21.40 and a beta of 1.27. MoonLake Immunotherapeutics has a 1 year low of $31.42 and a 1 year high of $61.87.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.14). During the same period in the previous year, the business earned ($0.39) earnings per share.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Several hedge funds have recently bought and sold shares of MLTX. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of MoonLake Immunotherapeutics by 17.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 42,236 shares of the company's stock worth $2,287,000 after purchasing an additional 6,422 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of MoonLake Immunotherapeutics by 44.6% during the first quarter. Victory Capital Management Inc. now owns 258,150 shares of the company's stock worth $10,086,000 after purchasing an additional 79,649 shares in the last quarter. New York State Common Retirement Fund purchased a new stake in shares of MoonLake Immunotherapeutics during the first quarter worth about $273,000. Rice Hall James & Associates LLC increased its position in shares of MoonLake Immunotherapeutics by 23.7% during the first quarter. Rice Hall James & Associates LLC now owns 137,516 shares of the company's stock worth $5,373,000 after acquiring an additional 26,383 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of MoonLake Immunotherapeutics during the fourth quarter worth about $3,485,000. Hedge funds and other institutional investors own 93.85% of the company's stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.